Comparative Pharmacology
Head-to-head clinical analysis: MEROPENEM versus VABOMERE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEROPENEM versus VABOMERE.
MEROPENEM vs VABOMERE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meropenem inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP 2 and PBP 3, leading to cell death.
Vabomere is a combination of meropenem, a carbapenem antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), and vaborbactam, a beta-lactamase inhibitor that protects meropenem from degradation by certain serine beta-lactamases, including extended-spectrum beta-lactamases (ESBLs) and Klebsiella pneumoniae carbapenemase (KPC).
1-2 g IV every 8 hours, infused over 15-30 minutes; typical dose 1 g q8h for complicated infections. Extended infusion over 3 hours may be used for resistant organisms.
Vabomere (meropenem and vaborbactam) 4 g (meropenem 2 g and vaborbactam 2 g) intravenously every 8 hours infused over 3 hours.
None Documented
None Documented
Clinical Note
moderateMeropenem + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Meropenem."
Clinical Note
moderateMeropenem + Valproic acid
"The serum concentration of Valproic acid can be decreased when it is combined with Meropenem."
Clinical Note
moderateMeropenem + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Meropenem."
1.0-1.5 hours in adults with normal renal function; prolonged to 4-6 hours in moderate renal impairment (CrCl 10-50 mL/min) and up to 7-10 hours in severe renal impairment (CrCl <10 mL/min).
The terminal elimination half-life is approximately 1 hour for meropenem and 2 hours for vaborbactam in patients with normal renal function. This short half-life supports three-times-daily dosing in patients with creatinine clearance ≥50 mL/min.
Renal: 70% unchanged via glomerular filtration and tubular secretion. Biliary: <2% excreted in bile. Fecal: ~2%.
Vabomere (meropenem and vaborbactam) is primarily excreted renally. Approximately 40-50% of meropenem and 75-95% of vaborbactam are excreted unchanged in urine. Biliary/fecal excretion is minimal (<2% for both).
Category A/B
Category C
Carbapenem Antibiotic
Carbapenem Antibiotic